CTSO logo

Cytosorbents (CTSO) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 August 2006

Indexes:

Not included

Description:

CTSO, or Cytosorbents, is a biomedical company that develops innovative therapies using blood purification technology. Their main product, CytoSorb, helps remove harmful substances from the blood during critical illnesses, improving patient outcomes in intensive care and surgery. The company focuses on enhancing patient safety and recovery.

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 05, 2014

Analyst ratings

Recent major analysts updates

12 Nov '24 D. Boral Capital
Buy
11 Nov '24 HC Wainwright & Co.
Neutral
08 Nov '24 EF Hutton
Buy
04 Nov '24 EF Hutton
Buy
22 Oct '24 EF Hutton
Buy
01 Oct '24 EF Hutton
Buy
14 Aug '24 HC Wainwright & Co.
Neutral
14 Aug '24 EF Hutton
Buy
29 July '24 EF Hutton
Buy
15 May '24 B. Riley Securities
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CTSO
globenewswire.com11 November 2024

PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
CTSO
seekingalpha.com09 November 2024

Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
CTSO
globenewswire.com13 August 2024

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024.

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CTSO
globenewswire.com13 August 2024

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J.

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CTSO
globenewswire.com07 August 2024

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024.

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CTSO
globenewswire.com30 July 2024

PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com.

CytoSorbents Secures $20 Million Credit Facility
CytoSorbents Secures $20 Million Credit Facility
CytoSorbents Secures $20 Million Credit Facility
CTSO
globenewswire.com02 July 2024

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P.

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
CTSO
Seeking Alpha14 March 2024

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
CTSO
Seeking Alpha09 November 2023

Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call
Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call
Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call
CTSO
Seeking Alpha01 August 2023

Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Cytosorbents?
  • What is the ticker symbol for Cytosorbents?
  • Does Cytosorbents pay dividends?
  • What sector is Cytosorbents in?
  • What industry is Cytosorbents in?
  • What country is Cytosorbents based in?
  • When did Cytosorbents go public?
  • Is Cytosorbents in the S&P 500?
  • Is Cytosorbents in the NASDAQ 100?
  • Is Cytosorbents in the Dow Jones?
  • When was Cytosorbents's last earnings report?
  • When does Cytosorbents report earnings?
  • Should I buy Cytosorbents stock now?

What is the primary business of Cytosorbents?

CTSO, or Cytosorbents, is a biomedical company that develops innovative therapies using blood purification technology. Their main product, CytoSorb, helps remove harmful substances from the blood during critical illnesses, improving patient outcomes in intensive care and surgery. The company focuses on enhancing patient safety and recovery.

What is the ticker symbol for Cytosorbents?

The ticker symbol for Cytosorbents is NASDAQ:CTSO

Does Cytosorbents pay dividends?

No, Cytosorbents does not pay dividends

What sector is Cytosorbents in?

Cytosorbents is in the Healthcare sector

What industry is Cytosorbents in?

Cytosorbents is in the Medical Devices industry

What country is Cytosorbents based in?

Cytosorbents is headquartered in United States

When did Cytosorbents go public?

Cytosorbents's initial public offering (IPO) was on 08 August 2006

Is Cytosorbents in the S&P 500?

No, Cytosorbents is not included in the S&P 500 index

Is Cytosorbents in the NASDAQ 100?

No, Cytosorbents is not included in the NASDAQ 100 index

Is Cytosorbents in the Dow Jones?

No, Cytosorbents is not included in the Dow Jones index

When was Cytosorbents's last earnings report?

Cytosorbents's most recent earnings report was on 7 November 2024

When does Cytosorbents report earnings?

The next expected earnings date for Cytosorbents is 14 March 2025

Should I buy Cytosorbents stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions